Parkinson's disease and dopamine transporter neuroimaging: a critical review.
Parkinson's disease (PD) is a common neurodegenerative disorder that is mainly caused by dopaminergic neuron loss in the substantia nigra. Several nuclear medicine radiotracers have been developed to evaluate PD diagnoses and disease evolution in vivo in PD patients. Positron emission tomography (PET) and single photon computerized emission tomography (SPECT) radiotracers for the dopamine transporter (DAT) provide good markers for the integrity of the presynaptic dopaminergic system affected in PD. Over the last decade, radiotracers suitable for imaging the DAT have been the subject of most efforts. In this review, we provide a critical discussion on the utility of DAT imaging for Parkinson's disease diagnosis (sensitivity and specificity).
Shih
Ming Chi
MC
Laboratório Interdisciplinar de Neuroimagem e Cognição, Universidade Federal de São Paulo, Rua Dr. Bacelar 334, CEP 04026-001 São Paulo, Brazil. mingchi@psuquiatria.epm.br
Hoexter
Marcelo Queiroz
MQ
Andrade
Luiz Augusto Franco de
LA
Bressan
Rodrigo Affonseca
RA
D015259:Dopamine Agents; D050483:Dopamine Plasma Membrane Transport Proteins; D006801:Humans; D015609:Organotechnetium Compounds; D010300:Parkinson Disease / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000592:standards*; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000592:standards*; D014326:Tropanes
D015259:Dopamine Agents; D050483:Dopamine Plasma Membrane Transport Proteins; D015609:Organotechnetium Compounds; D014326:Tropanes; C104196:technetium Tc 99m TRODAT-1